EAU Family of Journals

2023 Year in Review

Editor’s choice top articles published in the EAU family of journals in 2023. These articles are freely available to read, download and share through 30 April 2024.

Consider submitting your research for publication in an EAU journal. The journals offer both subscription and open access publishing options. We look forward to receiving your paper.

Editor-in-Chief: Alberto Briganti

Professor of Urology at Vita-Salute University San Raffaele, Milan, Italy where he also acts as deputy director of Urological Research Institute (URI).

• ●

  European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update(opens in new tab/window)

• ●

  Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022(opens in new tab/window)

• ●

  Phase 2 Single-arm Trial of Primary Retroperitoneal Lymph Node Dissection in Patients with Seminomatous Testicular Germ Cell Tumors with Clinical Stage IIA/B (PRIMETEST)(opens in new tab/window)

• ●

  Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2)(opens in new tab/window)

• ●

  Climate-smart Actions in the Operating Theatre for Improving Sustainability Practices: A Systematic Review(opens in new tab/window)

Editor-in-Chief: Morgan Rouprêt

Professor at APHP Sorbonne University, in the Academic Urology Department of the Pitié-Salpétrière Hospital, in Paris, France

• ●

  Best Current Practice and Research Priorities in Active Surveillance for Prostate Cancer—A Report of a Movember International Consensus Meeting(opens in new tab/window)

• ●

  Prognosis of Primary Papillary Ta Grade 3 Bladder Cancer in the Non–muscle-invasive Spectrum(opens in new tab/window)

• ●

  Application of Machine Learning Models to Predict Recurrence After Surgical Resection of Nonmetastatic Renal Cell Carcinoma(opens in new tab/window)

• ●

  Magnetic Resonance Imaging–based T-staging to Predict Biochemical Recurrence after Radical Prostatectomy: A Step Towards the iTNM Classification(opens in new tab/window)

• ●

  En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial(opens in new tab/window)

Editor-in-Chief: Christian Gratske

Professor and chair at the Department of Urology, Albert-Ludwigs-University in Freiburg, Germany

• ●

  Best Practice in Interventional Management of Urolithiasis: An Update from the European Association of Urology Guidelines Panel for Urolithiasis 2022(opens in new tab/window)

• ●

  Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis(opens in new tab/window)

• ●

  Outcomes of Robot-assisted Radical Prostatectomy with the Hugo RAS Surgical System: Initial Experience at a High-volume Robotic Center(opens in new tab/window)

• ●

  Life Cycle Assessment of Reusable and Disposable Cystoscopes: A Path to Greener Urological Procedures(opens in new tab/window)

• ●

  Relationship Between Age, Comorbidity, and the Prevalence of Erectile Dysfunction(opens in new tab/window)

Editor-in-Chief: Jochen Walz

Head of the Uro-Oncology department of the Institut Paoli-Calmettes Cancer Center in Marseille /France and specializes in Uro-Oncology

• ●

  The Patient Journey from Randomization to Detection of Prostate Cancer and Death: Results from ERSPC Rotterdam(opens in new tab/window)

• ●

  Comparative Effectiveness Randomized Clinical Trial Using Next-generation Microbial Sequencing to Direct Prophylactic Antibiotic Choice Before Urologic Stone Lithotripsy Using an Interprofessional Model(opens in new tab/window)

• ●

  Photodynamic Diagnosis-guided Transurethral Resection of Bladder Tumour in Participants with a First Suspected Diagnosis of Intermediate- or High-risk Non–muscle-invasive Bladder Cancer: Cost-effectiveness Analysis Alongside a Randomised Controlled Trial(opens in new tab/window)

• ●

  Quality of Life in Patients with High-grade Non–muscle-invasive Bladder Cancer Undergoing Standard Versus Reduced Frequency of Bacillus Calmette-Guérin Instillations: The EAU-RF NIMBUS Trial(opens in new tab/window)

• ●

  Location of Retroperitoneal Lymph Node Metastases in Upper Tract Urothelial Carcinoma: Results from a Prospective Lymph Node Mapping Study(opens in new tab/window)